Tachykinin receptor 3

From WikiMD's WELLNESSPEDIA


Tachykinin receptor 3 (TACR3) is a protein that in humans is encoded by the TACR3 gene. It is a member of the tachykinin receptor subfamily of G protein-coupled receptors that respond to the neuropeptide neurokinin B. This receptor is predominantly expressed in the central nervous system and plays a role in neurological processes and pain perception.

Function[edit]

Tachykinin receptor 3 is involved in various biological functions primarily mediated by its high affinity for the peptide neurokinin B, which is a member of the tachykinin peptide family. Neurokinin B binds to TACR3 triggering a series of intracellular events that influence neuronal excitability, neurotransmitter release, and the modulation of pain signals and other sensory processes.

Clinical Significance[edit]

Mutations in the TACR3 gene are associated with hypogonadotropic hypogonadism, a condition characterized by delayed or absent puberty and an impaired sense of smell. This is due to the role of TACR3 in regulating the release of gonadotropin-releasing hormone (GnRH), which is critical for the initiation and maintenance of puberty.

Pharmacology[edit]

Agonists for TACR3 include neurokinin B and the synthetic peptide senktide, both of which mimic the natural ligand's action at the receptor. Conversely, SB-222200 acts as an antagonist and blocks the receptor's function, which can be useful in experimental models to understand the physiological and pathological roles of TACR3.

See also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.